General Atlantic Portfolio
Our portfolio companies are already on a strong growth trajectory — our goal is to enhance it. We have a solid track record of delivering strategic, practical and impactful support to our portfolio companies.
Pharvaris is a clinical-stage company focused on the discovery and development of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE), a rare and potentially life-threatening genetic condition.
Hutchison China MediTech is an integrated biopharmaceutical company in China focused on innovative oncology therapies.
CANbridge is a biotechnology company focused on developing and commercializing rare disease therapeutics in China.
Royalty Pharma ×
Royalty Pharma is an innovative biopharma company with a leading portfolio of commercial and pre-commercial drug royalties.
Adagene is a clinical-stage biotechnology company focused on developing innovative antibodies with superior safety and efficacy profiles.
Allonnia leverages advanced technologies and biology to engineer breakthrough systems to develop and commercialize new waste remediation and management solutions.
Immunocore is a biotechnology company focused on therapies for oncology, viral diseases, and autoimmune disorders.
Ocumension is a clinical-stage biotechnology platform company focused on developing and commercializing innovative ophthalmology therapeutics in China.
Motif FoodWorks ×
Motif FoodWorks is a synthetic biology company that designs and sells ingredients to companies that make plant-based foods and beverages.
PathAI is a leading provider of AI-powered research tools and services for pathology.
Rubicon Research ×
Rubicon is a specialty generics pharmaceutical product-development company engaged in research, development and manufacturing of branded and specialty generic products and OTC products.
Ginkgo Bioworks ×
Ginkgo Bioworks is a synthetic biology company that designs and licenses DNA code for custom designed organisms.